View in EDS HTML Full Text PDF Full Text

Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study.

Saved in:
Bibliographic Details
Title: Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study.
Authors: Gupta P; VA Long Beach Healthcare System, Long Beach, CA 90822, USA.; Department of Medicine, University of California Irvine, Orange, CA 92868, USA., Gupta K; Department of Medicine, University of California Irvine, Orange, CA 92868, USA., Dockter T; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN 55905, USA., Harlos E; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN 55905, USA., Chow S; Alliance Protocol Operations Office, University of Chicago, Chicago, IL 60606, USA., Subbiah N; Alliance Protocol Operations Office, University of Chicago, Chicago, IL 60606, USA., Ruddy KJ; Department of Medical Oncology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN 55905, USA., Bazhenova L; Department of Medicine, University of California San Diego, San Diego, CA 92093, USA., Terstriep S; Sanford Roger Maris Cancer Center, Fargo, ND 58102, USA., Huang CH; VA Medical Center, Kansas City, MI 64128, USA.; University of Kansas Hospital-Westwood Cancer Center, Kansas City, MI 66205, USA., Kratzke RA; Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA., Vokes EE; Departments of Medicine and Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA., Loprinzi CL; Department of Medical Oncology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN 55905, USA.
Source: Cancers [Cancers (Basel)] 2026 Jan 25; Vol. 18 (3). Date of Electronic Publication: 2026 Jan 25.
Publication Type: Journal Article
Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41681846
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gupta+P%22">Gupta P</searchLink>; VA Long Beach Healthcare System, Long Beach, CA 90822, USA.; Department of Medicine, University of California Irvine, Orange, CA 92868, USA.<br /><searchLink fieldCode="AU" term="%22Gupta+K%22">Gupta K</searchLink>; Department of Medicine, University of California Irvine, Orange, CA 92868, USA.<br /><searchLink fieldCode="AU" term="%22Dockter+T%22">Dockter T</searchLink>; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN 55905, USA.<br /><searchLink fieldCode="AU" term="%22Harlos+E%22">Harlos E</searchLink>; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN 55905, USA.<br /><searchLink fieldCode="AU" term="%22Chow+S%22">Chow S</searchLink>; Alliance Protocol Operations Office, University of Chicago, Chicago, IL 60606, USA.<br /><searchLink fieldCode="AU" term="%22Subbiah+N%22">Subbiah N</searchLink>; Alliance Protocol Operations Office, University of Chicago, Chicago, IL 60606, USA.<br /><searchLink fieldCode="AU" term="%22Ruddy+KJ%22">Ruddy KJ</searchLink>; Department of Medical Oncology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN 55905, USA.<br /><searchLink fieldCode="AU" term="%22Bazhenova+L%22">Bazhenova L</searchLink>; Department of Medicine, University of California San Diego, San Diego, CA 92093, USA.<br /><searchLink fieldCode="AU" term="%22Terstriep+S%22">Terstriep S</searchLink>; Sanford Roger Maris Cancer Center, Fargo, ND 58102, USA.<br /><searchLink fieldCode="AU" term="%22Huang+CH%22">Huang CH</searchLink>; VA Medical Center, Kansas City, MI 64128, USA.; University of Kansas Hospital-Westwood Cancer Center, Kansas City, MI 66205, USA.<br /><searchLink fieldCode="AU" term="%22Kratzke+RA%22">Kratzke RA</searchLink>; Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.<br /><searchLink fieldCode="AU" term="%22Vokes+EE%22">Vokes EE</searchLink>; Departments of Medicine and Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA.<br /><searchLink fieldCode="AU" term="%22Loprinzi+CL%22">Loprinzi CL</searchLink>; Department of Medical Oncology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN 55905, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101526829%22">Cancers</searchLink> [Cancers (Basel)] 2026 Jan 25; Vol. 18 (3). <i>Date of Electronic Publication: </i>2026 Jan 25.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22MDPI%22">MDPI </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101526829 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2072-6694 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220726694%22">20726694 </searchLink><i>NLM ISO Abbreviation: </i>Cancers (Basel) <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41681846
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3390/cancers18030373
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gupta P
      – PersonEntity:
          Name:
            NameFull: Gupta K
      – PersonEntity:
          Name:
            NameFull: Dockter T
      – PersonEntity:
          Name:
            NameFull: Harlos E
      – PersonEntity:
          Name:
            NameFull: Chow S
      – PersonEntity:
          Name:
            NameFull: Subbiah N
      – PersonEntity:
          Name:
            NameFull: Ruddy KJ
      – PersonEntity:
          Name:
            NameFull: Bazhenova L
      – PersonEntity:
          Name:
            NameFull: Terstriep S
      – PersonEntity:
          Name:
            NameFull: Huang CH
      – PersonEntity:
          Name:
            NameFull: Kratzke RA
      – PersonEntity:
          Name:
            NameFull: Vokes EE
      – PersonEntity:
          Name:
            NameFull: Loprinzi CL
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 25
              M: 01
              Text: 2026 Jan 25
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 2072-6694
          Numbering:
            – Type: volume
              Value: 18
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Cancers
              Type: main
ResultId 1